Want to see AIXC full AI Analyst Report?
AIXC Stock Chart & Stats
$2.65
--
Market closed
$2.65
--
Day’s Range― - ―
52-Week Range$0.68 - $8.81
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.38M
Market Cap
$15.68M
Enterprise Value$8.84
Total Cash (Recent Filing)$6.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.23
Shares Outstanding20,234,993
10 Day Avg. Volume295,576
30 Day Avg. Volume2,383,814
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital Financing FlexibilityA committed equity facility of up to $50M provides durable financing optionality to fund R&D, platform launches and operations without adding debt. This reduces near-term insolvency risk and supports execution of strategic pivots, though draw terms and approvals will govern timing and dilution.
Low Leverage And Larger Equity BaseMinimal debt and a materially larger equity base give the company structural balance-sheet flexibility versus leveraged peers. Low interest obligations lower fixed-cost pressure and permit use of equity financing to sustain cash needs while pursuing product development and market entry.
Product/platform Launches And Strategic PartnershipsIntroducing RoboShare and AIXC01 targets durable, asset-light revenue rails (marketplace and infrastructure) and can create network effects over time. Combined with B2B/B2C platform work, these moves reposition the company into robotics/autonomy ecosystems with potential recurring revenue and ecosystem stickiness.
Bears Say
Pre-revenue With Widening LossesSustained pre-revenue status and materially larger TTM losses indicate the business model has not yet produced commercial traction. Over multiple quarters this undermines self-sufficiency, elevates dependency on capital markets and raises the bar for future profitability and return metrics.
Negative Operating Cash Flow And Cash BurnPersistent negative operating and free cash flow show the company consumes capital faster than it generates it, limiting runway (cash ~ $6.2M at quarter end) absent external financing. This structural cash-burn pattern forces dilution or sharp cost cuts unless revenue ramps.
Leadership Turnover And Legacy Business Wind-downA sweeping leadership reshuffle and winding down of prior biotech operations create execution risk and disrupt continuity. New leadership must deliver strategy execution and integrate platform initiatives while managing potential impairment charges, increasing operational and governance uncertainty.
AIxCrypto Holdings News
AIXC FAQ
What was AIxCrypto Holdings’s price range in the past 12 months?
AIxCrypto Holdings lowest stock price was $0.68 and its highest was $8.81 in the past 12 months.
What is AIxCrypto Holdings’s market cap?
AIxCrypto Holdings’s market cap is $15.68M.
When is AIxCrypto Holdings’s upcoming earnings report date?
AIxCrypto Holdings’s upcoming earnings report date is Aug 18, 2026 which is in 28 days.
How were AIxCrypto Holdings’s earnings last quarter?
AIxCrypto Holdings released its earnings results on May 11, 2026. The company reported -$0.789 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is AIxCrypto Holdings overvalued?
According to Wall Street analysts AIxCrypto Holdings’s price is currently Overvalued.
Does AIxCrypto Holdings pay dividends?
AIxCrypto Holdings does not currently pay dividends.
What is AIxCrypto Holdings’s EPS estimate?
AIxCrypto Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIxCrypto Holdings have?
AIxCrypto Holdings has 20,234,993 shares outstanding.
What happened to AIxCrypto Holdings’s price movement after its last earnings report?
AIxCrypto Holdings reported an EPS of -$0.789 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13%.
Which hedge fund is a major shareholder of AIxCrypto Holdings?
Currently, no hedge funds are holding shares in AIXC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIxCrypto Holdings
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Ownership Overview
―
Insiders
0.12% Mutual Funds
<0.01% Other Institutional Investors
98.66% Public Companies and
Individual Investors